HistoWiz

Somewhere in New York, a tray of mouse tissue goes into a machine on a Monday. By Wednesday, a researcher two time zones away is annotating the finished slide in a browser tab. No shipping. No waiting three weeks. No squinting down a microscope that lives in someone else's building. This is the ordinary miracle HistoWiz has spent more than a decade making boring.

Histopathology - the craft of slicing tissue thin enough to read disease in it - is one of the oldest tools in biology. It is also one of the slowest. For most of its history it ran on skilled hands, long queues, and the assumption that everyone simply accepted the queue. HistoWiz did not accept the queue.

01 / The ProblemThe bottleneck nobody bragged about

Why weeks of lab work stood between a question and an answer

Cancer research moves at the speed of its slowest experiment, and for a long time the slowest experiment was often the histology. A scientist would prepare tissue, hand it to a core facility, and wait. Weeks later the slides came back - sometimes inconsistent, sometimes mislabeled, always physical. To share them with a collaborator, you mailed glass across the country and hoped it arrived intact.

The frustration was personal before it was commercial. Founder Ke Cheng trained in cancer biology at Harvard Medical School and did postdoctoral work in Switzerland, where she ran into the same wall every researcher hits: the science was ready to move, and the slides were not. The bottleneck wasn't a mystery. It was just nobody's job to fix it.

02 / The BetA scientist trades the bench for robots

The wager: pathology is a logistics problem wearing a lab coat

Cheng's bet was unfashionable in the polite way good bets usually are. She wagered that histology's real problem wasn't scientific but operational - that if you automated the lab, standardized the output, and put every slide online the day it was made, you wouldn't just speed things up. You would change what researchers were willing to attempt.

HistoWiz started in Brooklyn in 2012 and went through Y Combinator's Winter 2016 batch. The pitch was plain: send us your tissue, get back digital slides, fast. The harder, quieter work was building a lab that ran like a factory and a platform that treated a whole-slide image like data instead of a keepsake.

03 / The ProductA microscope, turned into a web app

Precision histology up front, PathologyMap behind it

The front of the business is the lab: grossing, processing, embedding and sectioning paraffin and frozen tissue, routine H&E and a catalogue of special stains, immunostaining backed by more than 400 validated antibodies. The output is a publication-quality digital slide, often in three days.

The back of the business is PathologyMap - a cloud platform where those slides live. Researchers view, tag, annotate, store and share whole-slide images without ever shipping glass, and the database behind it is described as one of the largest preclinical pathology collections anywhere. Need a second opinion? A network of more than 100 board-certified and experimental pathologists is a few clicks away.

In 2024 the platform grew teeth. PathologyMap 2.0 added one-click AI analysis - automated quality control and tissue segmentation - plus a library of third-party AI apps, all on a pay-as-you-go model with no subscription and no software to install. The pitch is refreshingly unglamorous: run the analysis you need, pay for what you use, skip the procurement saga.

04 / The ProofMoney, customers, and a database that compounds

What 1,000 labs and $32 million say out loud

In October 2021 HistoWiz closed a $32 million Series A led by Vivo Capital, with venBio, Japanese conglomerate Asahi Kasei, and Shutterstock founder Jon Oringer joining in. Reported total funding sits near $36.7 million. The plan for the money was concrete: more robots, a flagship lab, AI-enabled services, and a Good Laboratory Practice histopathology lab in Miami.

The more durable proof is the customer count - over a thousand labs across academia, biotech and pharma - and the database those customers quietly build. Every slide processed makes PathologyMap a little more valuable to the next researcher. That is the kind of moat you cannot raise in a single round.

05 / The MissionStandardize the slow part of science

Faster, cleaner, shareable - so the science can be the bottleneck instead

Strip away the platform talk and the mission is modest in the best way: make the boring, slow, error-prone part of tissue research fast and consistent, so that researchers can spend their attention on the question rather than the queue. HistoWiz isn't trying to make the discovery. It's trying to get out of its way.

06 / TomorrowWhy a faster slide matters next year

When pathology becomes data, AI gets something to read

Here is the part that sneaks up on you. Once every slide is digital, standardized and stored in one place, you have built the exact thing modern AI is hungry for: a large, clean, labeled dataset. HistoWiz spent a decade turning glass into pixels because researchers needed speed. The byproduct is a pathology corpus that the next generation of models will want to learn from.

That is the long bet hiding inside the short one. Speed sold the service. Data may define the company. And in a field where a single answer can take years, shaving weeks off the slowest step is not a convenience - it is, occasionally, the difference between asking a question and never getting to.

Back to that tray of tissue that went into the machine on Monday. The old version of this story ends three weeks later with a padded envelope and a tracking number. The HistoWiz version ends Wednesday afternoon, with a slide on a screen and a collaborator already leaving comments. Same tissue. Same science. The only thing that changed is the wait - which, it turns out, was most of the problem all along.